Adamas Raises $40 Million To Battle Flu Pandemics
Emeryville, Calif.-based Adamas has been working in stealth mode for at least three years to develop an anti-viral drug for flu pandemics, including the H1N1 virus (aka swine flu). "A pandemic is a horrible problem to face as a healthcare system and as individuals, but you probably understand as a private equity reporter that it's an unprecedented opportunity to do clinical trials in a short period of time (because the motivation to find a vaccine is so high)," said Adamas Chairman and CEO Gregory Went. "More people die of flu than you realize." Adamas is working on a triple-combination drug to fight flu because all flus have grown resistant to single drugs, he said. A similar strategy was used against tuberculosis, HIV, Hepatitis C and other diseases.
